SG11202012869SA - Heteroaryl compounds for treating huntington's disease - Google Patents
Heteroaryl compounds for treating huntington's diseaseInfo
- Publication number
- SG11202012869SA SG11202012869SA SG11202012869SA SG11202012869SA SG11202012869SA SG 11202012869S A SG11202012869S A SG 11202012869SA SG 11202012869S A SG11202012869S A SG 11202012869SA SG 11202012869S A SG11202012869S A SG 11202012869SA SG 11202012869S A SG11202012869S A SG 11202012869SA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- heteroaryl compounds
- treating huntington
- huntington
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690540P | 2018-06-27 | 2018-06-27 | |
| PCT/US2019/038895 WO2020005877A1 (en) | 2018-06-27 | 2019-06-25 | Heteroaryl compounds for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012869SA true SG11202012869SA (en) | 2021-01-28 |
Family
ID=67185796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012869SA SG11202012869SA (en) | 2018-06-27 | 2019-06-25 | Heteroaryl compounds for treating huntington's disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210284660A1 (pt) |
| JP (2) | JP7515415B2 (pt) |
| KR (1) | KR20210038845A (pt) |
| CN (1) | CN112805280A (pt) |
| AU (2) | AU2019294482B2 (pt) |
| BR (1) | BR112020026534A2 (pt) |
| CA (1) | CA3104516A1 (pt) |
| EA (1) | EA202092899A1 (pt) |
| IL (1) | IL279714A (pt) |
| MX (1) | MX2020014315A (pt) |
| SG (1) | SG11202012869SA (pt) |
| WO (1) | WO2020005877A1 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
| WO2018226622A1 (en) | 2017-06-05 | 2018-12-13 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| EP3644996B1 (en) | 2017-06-28 | 2023-07-26 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
| CA3067592A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| WO2019028440A1 (en) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| WO2020005873A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| JP2022521467A (ja) | 2019-02-05 | 2022-04-08 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP2022519323A (ja) | 2019-02-06 | 2022-03-22 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| US20240216369A1 (en) | 2019-11-01 | 2024-07-04 | Novartis Ag | The use of a splicing modulator for a treatment slowing progression of huntington's disease |
| US20230322754A1 (en) * | 2020-04-28 | 2023-10-12 | Kymera Therapeutics, Inc. | Irak inhibitors and uses thereof |
| TW202208358A (zh) | 2020-05-13 | 2022-03-01 | 美商Ｃｈｄｉ基金會股份有限公司 | 用於治療亨汀頓舞蹈症之htt調節劑 |
| MX2023000167A (es) | 2020-07-02 | 2023-05-03 | Remix Therapeutics Inc | Derivados de 5-[5-(piperidin-4-il)tieno[3,2-c]pirazol-2-il]indazol y compuestos relacionados como moduladores para el corte y empalme de ácidos nucleicos y para el tratamiento de enfermedades proliferativas. |
| IL299543A (en) | 2020-07-02 | 2023-02-01 | Remix Therapeutics Inc | 2-(Indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as nucleic acid splicing modulators and for the treatment of multiple diseases |
| JP2024510487A (ja) * | 2021-03-17 | 2024-03-07 | エフ． ホフマン－ラ ロシュ アーゲー | 新規なチアジアゾロピリミドン誘導体 |
| EP4308576A1 (en) * | 2021-03-17 | 2024-01-24 | F. Hoffmann-La Roche AG | New thiazolopyrimidinone derivatives |
| EP4308572A1 (en) * | 2021-03-17 | 2024-01-24 | F. Hoffmann-La Roche AG | New thienopyrimidinone derivatives |
| TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| CN116262758A (zh) * | 2021-12-15 | 2023-06-16 | 上海博悦生物科技有限公司 | 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途 |
| WO2023225244A1 (en) * | 2022-05-20 | 2023-11-23 | Biogen Ma Inc. | Heterocyclic compounds for treating huntington's disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004019002A2 (en) * | 2002-08-23 | 2004-03-04 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent glycosides and methods for their use |
| US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
| CN101410385B (zh) * | 2006-03-28 | 2011-08-24 | 高点制药有限责任公司 | 具有组胺h3受体活性的苯并噻唑类 |
| US8153813B2 (en) * | 2007-12-20 | 2012-04-10 | Abbott Laboratories | Benzothiazole and benzooxazole derivatives and methods of use |
| WO2009114874A2 (en) * | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| US20090258907A1 (en) * | 2008-04-09 | 2009-10-15 | Abbott Laboratories | Compounds useful as inhibitors of rock kinases |
| WO2010024903A1 (en) * | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
| US8283360B2 (en) * | 2008-12-19 | 2012-10-09 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic derivatives and methods of use thereof |
| US8940716B2 (en) * | 2010-05-06 | 2015-01-27 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as GPR119 modulators |
| EP2560008B1 (en) * | 2011-08-18 | 2016-11-30 | Korea Institute of Science and Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
| CN107207526A (zh) * | 2014-12-02 | 2017-09-26 | 拜耳作物科学股份公司 | 作为害虫防治剂的双环化合物 |
| CN107635984B (zh) * | 2015-03-11 | 2021-04-13 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| ES2879995T3 (es) * | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
| CN109071528B (zh) * | 2016-03-11 | 2023-02-17 | Ac免疫有限公司 | 用于诊断和治疗的双环化合物 |
| US10526345B2 (en) * | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
| US10730868B2 (en) * | 2016-07-14 | 2020-08-04 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
-
2019
- 2019-06-25 MX MX2020014315A patent/MX2020014315A/es unknown
- 2019-06-25 AU AU2019294482A patent/AU2019294482B2/en active Active
- 2019-06-25 US US17/254,828 patent/US20210284660A1/en active Pending
- 2019-06-25 SG SG11202012869SA patent/SG11202012869SA/en unknown
- 2019-06-25 CN CN201980050967.1A patent/CN112805280A/zh active Pending
- 2019-06-25 WO PCT/US2019/038895 patent/WO2020005877A1/en unknown
- 2019-06-25 BR BR112020026534-9A patent/BR112020026534A2/pt unknown
- 2019-06-25 KR KR1020207036998A patent/KR20210038845A/ko not_active Application Discontinuation
- 2019-06-25 EA EA202092899A patent/EA202092899A1/ru unknown
- 2019-06-25 JP JP2020572894A patent/JP7515415B2/ja active Active
- 2019-06-25 CA CA3104516A patent/CA3104516A1/en active Pending
-
2020
- 2020-12-23 IL IL279714A patent/IL279714A/en unknown
-
2022
- 2022-07-28 AU AU2022209304A patent/AU2022209304A1/en not_active Abandoned
-
2024
- 2024-04-26 JP JP2024072881A patent/JP2024105367A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL279714A (en) | 2021-03-01 |
| JP2021528466A (ja) | 2021-10-21 |
| KR20210038845A (ko) | 2021-04-08 |
| AU2019294482A1 (en) | 2021-01-21 |
| AU2019294482B2 (en) | 2022-09-01 |
| JP7515415B2 (ja) | 2024-07-12 |
| CA3104516A1 (en) | 2020-01-02 |
| EA202092899A1 (ru) | 2021-05-14 |
| MX2020014315A (es) | 2021-05-27 |
| JP2024105367A (ja) | 2024-08-06 |
| WO2020005877A1 (en) | 2020-01-02 |
| EP3814345B1 (en) | 2024-09-25 |
| CN112805280A (zh) | 2021-05-14 |
| AU2022209304A1 (en) | 2022-08-25 |
| US20210284660A1 (en) | 2021-09-16 |
| BR112020026534A2 (pt) | 2021-03-23 |
| EP3814345A1 (en) | 2021-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279714A (en) | Heteroaryl compounds for the treatment of Huntington's disease | |
| IL277497A (en) | Compounds for the treatment of Huntington's disease | |
| IL271046A (en) | Compounds for the treatment of Huntington's disease | |
| IL279688A (en) | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease | |
| IL287945A (en) | Compounds for the treatment of Huntington's disease | |
| IL281633A (en) | Methods for treating Huntington's disease | |
| EP3644996A4 (en) | HUNTINGTON'S DISEASE TREATMENT METHODS | |
| EP3645121A4 (en) | HUNTINGTON'S DISEASE TREATMENT METHODS | |
| IL275265A (en) | Macrocyclic compounds for the treatment of disease | |
| EP3426260A4 (en) | FOR THE TREATMENT OF DISEASES USEFUL C-GLYCOSIDE COMPOUNDS | |
| GB201714027D0 (en) | Antisense oligonucleotides for the treatment of huntington's disease | |
| PL3285755T3 (pl) | Chlorowodorek kreatyny do leczenia choroby Huntingtona | |
| IL288793A (en) | Compounds for the treatment of respiratory diseases | |
| EP3429569A4 (en) | METHODS FOR PREVENTING OR TREATING PARKINSON'S DISEASE BY FARNESYLATION DE PARIS | |
| IL268008A (en) | Ppargamma agonist for the treatment of huntington's disease | |
| EP4076656A4 (en) | METHODS OF TREATMENT OF HUNTINGTON’S DISEASE | |
| SG11202101274XA (en) | Benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease | |
| EP3843724A4 (en) | BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | |
| EP3814345B8 (en) | Heteroaryl compounds for treating huntington's disease | |
| ZA202006126B (en) | Compounds for treating alzheimer's disease | |
| EP3774744A4 (en) | Compounds for treating huntington's disease | |
| GB201917691D0 (en) | Compounds for treating respiratory disease | |
| GB201908453D0 (en) | Compounds for treating respiratory disease | |
| GB201908451D0 (en) | Compounds for treating respiratory disease | |
| GB201808464D0 (en) | Pharmaceutical compounds for use in treating huntington's disease |